keyword
MENU ▼
Read by QxMD icon Read
search

urothelium cancer

keyword
https://www.readbyqxmd.com/read/28434947/effect-of-urinary-cytology-for-detecting-recurrence-in-remnant-urothelium-after-radical%C3%A2-cystectomy-insights-from-a-10-year-cytology-database
#1
Renate Pichler, Gennadi Tulchiner, Wilhelm Oberaigner, Georg Schaefer, Wolfgang Horninger, Andrea Brunner, Isabel Heidegger
BACKGROUND: We evaluated the diagnostic accuracy of urinary cytology (UCy) for detecting recurrence in the remnant urothelium (RRU) after radical cystectomy (RC) for urothelial cancer. PATIENTS AND METHODS: We conducted a 10-year retrospective analysis of a prospectively collected, single-center RC database comprising 177 patients who had undergone follow-up examinations at our department with ≥ 1 available postoperative UCy specimen. UCy specimens were classified using the Papanicolaou scheme...
March 30, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28431768/is-there-room-for-luminal-basal-urothelial-cell-population-quantification
#2
G R Passos, J A Camargo, K L Ferrari, G C Franch, A E Nowill, L O Reis
PURPOSE: Three cell layers compose the urothelium: basal, intermediate and luminal ("umbrella cells") and different diseases might arise from different cell populations. The aim of this study is to analyze the quantification ability of such cell populations by using four different protocols. METHODS: Twenty male rats (Wistar) were randomized in four groups of five animals: scraping, enzymatic 30, 45 and 60minutes. The cells were isolated, analyzed by flow cytometer and data processed by BD FACSDIVA™ software...
April 18, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28428106/gata3-immunohistochemistry-in-urothelial-carcinoma-of-the-upper-urinary-tract-as-a-urothelial-marker-as-well-as-a-prognosticator
#3
Satoshi Inoue, Taichi Mizushima, Kazutoshi Fujita, Abdelrazak Meliti, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, George J Netto, Norio Nonomura, Hiroshi Miyamoto
Immunohistochemistry of a transcription factor, GATA3, has been widely used as a promising urothelial marker in diagnostic surgical pathology practice. However, the expression status of GATA3 in upper urinary tract urothelial carcinomas (UUTUCs) and its prognostic significance have not been fully investigated. We immunohistochemically stained for GATA3 in 99 UUTUC samples and paired non-neoplastic urothelial tissues. GATA3 was positive in 51 [51.5%; 32 (32.3%) weak, 11 (11.1%) moderate, 8 (8.1%) strong] of 99 UUTUCs, which was significantly lower than in benign urothelium [79 (96...
April 17, 2017: Human Pathology
https://www.readbyqxmd.com/read/28419193/a-randomized-phase-ii-iii-study-of-cabazitaxel-versus-vinflunine-in-metastatic-or-locally-advanced-transitional-cell-carcinoma-of-the-urothelium-secavin
#4
J Bellmunt, J M Kerst, F Vázquez, R Morales-Barrera, E Grande, A Medina, Mªb González Graguera, G Rubio, U Anido, O Fernández Calvo, E González-Billalabeitia, Ajm Van den Eertwegh, E Pujol, J L Perez-Gracia, J L González Larriba, R Collado, M Los, S Maciá, R De Wit
BACKGROUND: Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first and second line. Vinflunine is the only treatment approved in this setting by the European Medicines Agency (EMA) and taxanes are also widely used in second line. Cabazitaxel is a taxane with activity in docetaxel-refractory cancers. A randomized study was conducted to compare its efficacy vs vinflunine. PATIENTS AND METHODS: This is a multicenter, randomized, open-label, phase II/III study, following a Simon's optimal method with stopping rules based on an interim futility analysis and a formal efficacy analysis at the end of the phase II...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28415801/identification-of-long-non-coding-rnas-that-stimulate-cell-survival-in-bladder-cancer
#5
Aleksandra M Dudek, Sabrina J Boer, Nanda Boon, J Alfred Witjes, Lambertus A L M Kiemeney, Gerald W Verhaegh
For many years, research on the biology underlying bladder cancer focused on protein-coding genes which cover only about 3% of the human genome. Recently, it was discovered that a large part of the human genome is actively transcribed as long non-coding RNAs (lncRNAs). LncRNAs are master regulators of gene expression and several lncRNAs were shown to play a role in bladder cancer development and progression. Here, we analyzed lncRNA expression in muscle-invasive bladder cancer (MIBC) using the MiTranscriptome database of cancer lncRNA expression profiles, and we studied their function in bladder cancer-derived tumor cells...
March 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28403596/blue-light-cystoscopy-with-hexylaminolevulinate-our-7-years-experience
#6
Vito Lacetera, Ubaldo Cantoro, Lorenzo Montesi, Daniele Cantoro, Bernardo Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Domenico Milella, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Valerio Beatrici
AIM: The objective of the present study is to evaluate the diagnostic accuracy of hexylaminolevulinate (HAL) blue light cystoscopy compared with standard white light cystoscopy (WLC) in daily practice. MATERIALS AND METHODS: An observational, comparative, controlled (within patient) study was carried out at our Center. 61 consecutive patients with suspected or confirmed bladder cancer were recruited for the study from January 2008 until January 2015. Patients with suspected bladder cancer (positive cytology with negative WLC) or history of previous high-grade NMIBC or CIS were included in the study...
March 31, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28373455/comparison-of-efficacy-of-adjuvant-mec-methotrexate-epirubicin-and-cisplatin-and-gc-gemcitabine-and-cisplatin-in-advanced-upper-tract-urothelial-carcinoma
#7
Sheng-Chun Hung, Shian-Shiang Wang, Chun-Kuang Yang, Jian-Ri Li, Chen-Li Cheng, Yen-Chuan Ou, Hao-Chung Ho, Kun-Yuan Chiu, Chuan-Shu Chen
AIM: To evaluate the efficacy of methotrexate, epirubicin and cisplatin (MEC) or gemcitabine and cisplatin (GC) as adjuvant chemotherapy in advanced upper tract urothelium carcinoma (UTUC). PATIENTS AND METHODS: From 2002 January to 2008 December, a total of 70 patients with advanced UTUC received radical nephroureterctomy at our Institute with MEC and GC as adjuvant chemotherapy. Disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) among the two groups were evaluated...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28367434/mediator-complex-subunit-med1-protein-expression-is-decreased-during-bladder-cancer-progression
#8
Niklas Klümper, Isabella Syring, Wenzel Vogel, Doris Schmidt, Stefan C Müller, Jörg Ellinger, Zaki Shaikhibrahim, Johannes Brägelmann, Sven Perner
INTRODUCTION: Bladder cancer (BCa) is among the most frequent cancer entities and relevantly contributes to cancer-associated deaths worldwide. The multi-protein Mediator complex is a central regulator of the transcriptional machinery of protein-coding genes and has been described to be altered in several malignancies. MED1, a subunit of the tail module, was described to negatively modulate expression of metastasis-related genes and to be downregulated in melanoma and lung cancer. In contrast, MED1 hyperactivity was described in breast and prostate cancer, likely due its function as a hub for nuclear hormone receptors...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28327458/nfatc1-expression-as-a-prognosticator-in-urothelial-carcinoma-of-the-upper-urinary-tract
#9
Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, Norio Nonomura, Hiroshi Miyamoto
We recently found that NFATc1, a member of the NFAT family and a key regulator of the immune response, could induce bladder carcinogenesis and cancer progression. In this study, we immunohistochemically stained for NFATc1 in upper urinary tract urothelial carcinoma (UUTUC) specimens and paired nonneoplastic urothelial tissues. NFATc1 was positive in 51 [52%; 40 (40%) weak (1+), 9 (9%) moderate (2+), and 2 (2%) strong (3+)] of 99 UUTUCs, which was significantly higher than in benign urothelium [30 (36%) of 83; 28 (34%) weak and 2 (2%) moderate] (0 vs 1+/2+/3+, P=...
March 16, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28257819/in-vitro-and-ex-vivo-permeability-studies-of-paclitaxel-and-doxorubicin-from-drug-eluting-biodegradable-ureteral-stents
#10
Alexandre A Barros, Carlos Oliveira, Rui L Reis, Estevão Lima, Ana Rita C Duarte
A drug-eluting biodegradable ureteral stent (BUS) has been developed as a new approach for the treatment of urothelial tumors of upper urinary tract cancer. In a previous work, this system has proven to be a good carrier for anticancer drugs as a potential effective and sustainable intravesical drug delivery (IDD) system. BUS has revealed to reduce in 75% the viability of human urothelial cancer cells (T24) after 72 h of contact and demonstrated minimal cytotoxic effect on human umbilical vein endothelial cells (HUVECs) which were used as a control...
February 28, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28248032/-the-risk-of-bladder-cancer-in-patients-with-prostatic-hyperplasia-and-strategies-to-manage-this-combination
#11
Yu G Alyaev, A M Pshikhachev, A N Perekalina
The combination of bladder cancer with benign prostatic hyperplasia (BPH) occurs in 5-27% of cases. The link between these diseases has not yet been closely investigated. The main role in the pathogenesis of bladder cancer combined with BPH is played by the residual urine and prolonged exposure of urothelium to the urine carcinogens. The choice of surgical treatment modality for the combination of non-muscle invasive bladder cancer and BPH is still a matter of debate. There is no consensus on the safety and appropriateness of simultaneous transurethral resection of the bladder and prostate in these patients...
November 2016: Urologii︠a︡
https://www.readbyqxmd.com/read/28240746/epithelial-mesenchymal-transition-promotes-sox2-and-nanog-expression-in-bladder-cancer
#12
Toshiro Migita, Ayano Ueda, Tomokazu Ohishi, Megumi Hatano, Hiroyuki Seimiya, Shin-Ichiro Horiguchi, Fumitaka Koga, Futoshi Shibasaki
Bladder cancer is the most common malignant tumor of the urothelium and is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Stemness markers such as SOX2 and NANOG are frequently overexpressed in various aggressive cancers, including MIBC; epithelial-mesenchymal transition (EMT) has been proposed as a potential trigger of stemness in cancers. To determine whether cancer stemness is acquired via EMT in bladder cancer, we studied the effect of EMT on the expression of SOX2 and NANOG in bladder cancer cell lines...
February 27, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28237713/poly-l-glutamic-acid-drug-delivery-system-for-the-intravesical-therapy-of-bladder-cancer-using-wga-as-targeting-moiety
#13
C Apfelthaler, M Anzengruber, F Gabor, M Wirth
In the management of bladder cancer, surgical resection of the tumour is usually followed by intravesical instillation of immunomodulatives and/or chemotherapeutics. The purpose of this local intravesical therapy is to eliminate residual malignant cells after surgical intervention. The main limitation of a localised adjuvant therapy is the insufficient concentration of the active pharmaceutical ingredient (API) in malignant cells due to the unique structure of the human urothelium making it an exclusively hard to overcome barrier in the human body...
February 22, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28228618/preventive-effect-of-intravesical-ozone-supplementation-on-n-methyl-n-nitrosourea-induced-non-muscle-invasive-bladder-cancer-in-male-rats
#14
Kerem Teke, Tayyar A Ozkan, Oguz O Cebeci, Hasan Yilmaz, Muhammed E Keles, Levend Ozkan, Meltem O Dillioglugil, Demir K Yildiz, Ozdal Dillioglugil
Although non-muscle invasive bladder cancer (NMIBC) is widely seen in men, most laboratory studies of new intravesical therapies to prevent NMIBC have been conducted on female animals. In addition, ozone (O3) has been shown to be a beneficial agent as an intravesical application in the treatment of various disorders. In the current study, we evaluated the immunohistopathological oxidative-antioxidative effects of intravesical O3 treatment on n-methyl-n-nitrosourea (MNU)-induced NMIBC. Male Wistar-Albino rats (n=51) were divided into four groups: sham (n=6), O3 only (n=15), MNU only (n=15), and MNU+O3 (n=15)...
February 22, 2017: Experimental Animals
https://www.readbyqxmd.com/read/28163793/uromark-a-urinary-biomarker-assay-for-the-detection-of-bladder-cancer
#15
Andrew Feber, Pawan Dhami, Liqin Dong, Patricia de Winter, Wei Shen Tan, Mónica Martínez-Fernández, Dirk S Paul, Antony Hynes-Allen, Sheida Rezaee, Pratik Gurung, Simon Rodney, Ahmed Mehmood, Felipe Villacampa, Federico de la Rosa, Charles Jameson, Kar Keung Cheng, Maurice P Zeegers, Richard T Bryan, Nicholas D James, Jesus M Paramio, Alex Freeman, Stephan Beck, John D Kelly
BACKGROUND: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay to diagnose BC from urine with high sensitivity and specificity...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28149932/aquaporin-3-expression-loss-in-urothelial-carcinoma-association-with-tumor-invasion-depth-but-not-with-grading
#16
Johannes Breyer, Wolfgang Otto, Maximilian Burger, Arndt Hartmann, Peter C Rubenwolf
We have previously provided molecular evidence of expression of aquaporin 3 (AQP3) in normal human urothelium and in UBC of various stages. Whereas former studies demonstrated that loss of AQP3 was associated with invasive and high-grade disease and worse progression-free and cancer-specific survival, this report investigates the expression of AQP3 in associated CIS. Contrary to what we had expected, all CIS specimens were shown to exhibit strong AQP3 expression, suggesting loss of AQP3 in UBC is primarily associated with the ability of tumor cells for invasion but not with grading as sign of dedifferentiation...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28109014/urothelial-generation-and-regeneration-in-development-injury-and-cancer
#17
REVIEW
Caihong Wang, Whitney Trotter Ross, Indira U Mysorekar
Homeostatic maintenance and repair of the urothelium upon injury are required for a functional bladder in both healthy and disease conditions. Understanding the cellular and molecular mechanisms underlying the urothelial regenerative response is key to designing strategies for tissue repair and ultimately treatments for urologic diseases including urinary tract infections, voiding dysfunction, painful bladder syndrome, and bladder cancer. In this article, we review studies on urothelial ontogeny during development and regeneration following various injury modalities...
April 2017: Developmental Dynamics: An Official Publication of the American Association of Anatomists
https://www.readbyqxmd.com/read/28101348/evans-blue-mediated-white-light-detection-of-non-muscle-invasive-bladder-cancer-a-preclinical-feasibility-and-safety-study-using-a-rat-bladder-urothelial-cell-carcinoma-model
#18
Sanne Elsen, Evelyne Lerut, Frank Van Der Aa, Ben Van Cleynenbreugel, Hendrik Van Poppel, Peter De Witte
Photodynamic diagnosis (PDD) improves the detection of non-muscle-invasive bladder cancer (NMIBC). However, white-light (WL) cystoscopy remains the technique routinely used in urological clinics. A more cost-effective but equally performant alternative to PDD may encompass the use of an intense tumoritropic dye in combination with WL cystoscopy. Using a preclinical setting, we investigated the practical aspects of the use of Evans blue (EB) dye for the possible future detection of NMIBC using WL cystoscopy...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28081549/microrna-promoter-methylation-a-new-tool-for-accurate-detection-of-urothelial-carcinoma
#19
Nuno André Padrão, Sara Monteiro-Reis, Jorge Torres-Ferreira, Luís Antunes, Luís Leça, Diana Montezuma, João Ramalho-Carvalho, Paula C Dias, Paula Monteiro, Jorge Oliveira, Rui Henrique, Carmen Jerónimo
BACKGROUND: Urothelial carcinoma (UC) is the most common cancer affecting the urinary system, worldwide. Lack of accurate early detection tools entails delayed diagnosis, precluding more efficient and timely treatment. In a previous study, we found that miR-129-2 and miR-663a were differentially methylated in UC compared with other genitourinary tract malignancies. Here, we evaluated the diagnostic performance of those microRNAs in urine. METHODS: Promoter methylation levels of miR-129-2 and miR-663a were assessed, using real-time quantitative methylation-specific PCR, in UC tissue samples (using normal urothelium as control) and, subsequently, in urine samples from UC and other genitourinary malignancies...
February 28, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28074261/perioperative-chemotherapy-in-upper-tract-urothelial-carcinoma-a-comprehensive-review
#20
REVIEW
Atiqullah Aziz, Jakub Dobruch, Kees Hendricksen, Luis A Kluth, Andrea Necchi, Aidan Noon, Michael Rink, Florian Roghmann, Roland Seiler, Paolo Gontero, Wassim Kassouf, Shahrokh F Shariat, Evanguelos Xylinas
PURPOSE: To evaluate the role of neoadjuvant (NAC) and adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: A comprehensive review of the current literature was performed searching for all studies investigating NAC and AC in UTUC in MEDLINE and https://clinicaltrials.gov , prior to April 2016. The following keywords were used: "ureteral neoplasms," "urothelium," "ureter," "upper tract urothelial," "chemotherapy," "adjuvant," "neoadjuvant" and relevant variants...
January 10, 2017: World Journal of Urology
keyword
keyword
53999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"